Tag: BriaCell Therapeutics

October 7, 2019

BriaCell CEO: Incyte Collaboration Enabling New Clinical Trials for Breast Cancer Treatments

BriaCell Therapeutics CEO Dr. Bill Williams joined the Investing News Network to discuss his company's progress in developing an innovative...
December 19, 2018

Biotech Outlook 2019: Will the Pressure Continue?

With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
April 3, 2018

BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal

BriaCell Therapeutics Corp. ("BriaCell") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to...
March 27, 2018

BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment With Leading U.S. Biotech Funds

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology,...
March 8, 2018

BriaCell Announces Proposed Investment by Leading Biotech Funds

BriaCell Therapeutics (TSXV:BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it expects to...
March 8, 2018

BriaCell Announces Proposed Investment by Leading Biotech Funds and Concurrent Non-Brokered Financing for aggregate gross proceeds of up to $4.8 Million

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology,...
January 31, 2018

BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT™

BriaCell Therapeutics Corp.("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on...